Last reviewed · How we verify

CagriSema — Competitive Intelligence Brief

CagriSema (CagriSema) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual GLP-1/glucagon receptor agonist. Area: Endocrinology / Diabetes.

phase 3 Dual GLP-1/glucagon receptor agonist GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CagriSema (CagriSema) — Novo Nordisk A/S. CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CagriSema TARGET CagriSema Novo Nordisk A/S phase 3 Dual GLP-1/glucagon receptor agonist GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual GLP-1/glucagon receptor agonist class)

  1. AstraZeneca · 1 drug in this class
  2. Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CagriSema — Competitive Intelligence Brief. https://druglandscape.com/ci/cagrisema. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: